Paris, France

Caroline Ligeour

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Centre National De La Recherche Scientifique, Universitè De Montpellier. Active years: 2018.


 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2018

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Caroline Ligeour: Innovator in Antibacterial Research

Introduction

Caroline Ligeour is a prominent inventor based in Paris, France. She has made significant contributions to the field of antibacterial research, particularly through her innovative work on glycoclusters. Her research focuses on developing effective methods for combating bacterial infections.

Latest Patents

Caroline Ligeour holds a patent for "Glycoclusters and their pharmaceutical use as antibacterials." This patent describes a molecule that responds to the formula (I) of the glycocluster type, featuring galactose residues at their extremities. The patent outlines simple and efficient methods for preparing these compounds, emphasizing their medical use as inhibitors of infections, specifically targeting bacterial virulence.

Career Highlights

Throughout her career, Caroline has worked with esteemed institutions such as the Centre National de la Recherche Scientifique and Université de Montpellier. Her dedication to research and innovation has positioned her as a key figure in the scientific community.

Collaborations

Caroline has collaborated with notable colleagues, including François Morvan and Jean-Jacques Vasseur. These partnerships have further enriched her research and contributed to advancements in antibacterial therapies.

Conclusion

Caroline Ligeour's work exemplifies the impact of innovative research in the fight against bacterial infections. Her contributions to the field of glycoclusters highlight the importance of scientific exploration in developing new medical solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…